美国成年癌症幸存者中的物质使用障碍
本横断面研究利用2015至2020年美国全国药物使用与健康调查(NSDUH)数据,纳入6101名成年实体瘤癌症幸存者,按DSM-IV标准定义物质使用障碍(SUD),计算过去12个月活动性SUD的加权患病率。终生癌症幸存者中活动性SUD患病率为3.83%(SE,0.32%),以头颈癌(9.36%)、食管癌和胃癌(9.42%)、宫颈癌(6.24%)及黑色素瘤(6.20%)较高。作者认为该信息可用于识别可能受益于肿瘤与SUD整合照护的癌症幸存者。
要点
- 终生癌症幸存者活动性SUD加权患病率为3.83%(SE,0.32%)。
- 头颈癌9.36%、食管癌和胃癌9.42%、宫颈癌6.24%、黑色素瘤6.20%为高患病瘤种。
- 近12个月确诊者总体SUD为3.81%(SE,0.74%),头颈癌达18.73%、宫颈癌达15.70%。
核心结论
- 作者认为某些类型癌症幸存者的SUD患病率较高,该信息可用于识别可能受益于肿瘤与SUD整合照护的癌症幸存者。
- 作者提出,未来理解和解决成年癌症幸存者共病SUD需求的工作应优先关注SUD患病率高的癌症人群。
研究设计与样本
- 横断面研究,使用2015至2020年每年实施的美国全国药物使用与健康调查(NSDUH)数据,识别有实体瘤病史的成年人。
- SUD定义为满足《精神障碍诊断与统计手册(第四版)》滥用4条标准中至少1条或依赖6条标准中至少3条。
- 按NSDUH指南调整分析权重,将合并数据集中提供的权重除以合并数据年数(如2015-2020年为6年)。
- 计算任何终生癌症史受访者过去12个月活动性SUD的加权患病率及相应标准误(均以百分比表示),并在二次分析中计算调查前12个月内确诊癌症的受访者。
- 共纳入6101名成年癌症幸存者,其中56.91%年龄在65岁及以上,61.63%为女性;数据分析时间为2022年7月至2023年6月。
主要发现
- 终生癌症幸存者中活动性SUD患病率为3.83%(SE,0.32%)。
- SUD患病率较高的瘤种为头颈癌(包括口腔、舌、唇、喉和咽癌;9.36%[SE,2.47%])、食管癌和胃癌(9.42%[SE,5.51%])、宫颈癌(6.24%[SE,1.41%])和黑色素瘤(6.20%[SE,1.34%])。
- 酒精使用障碍是总体最常见的SUD(2.78%[SE,0.26%]),也是头颈癌、宫颈癌和黑色素瘤幸存者中最常见的SUD。
- 食管癌和胃癌幸存者中最常见的SUD为大麻使用障碍(9.42%[SE,5.51%])。
- 过去12个月内确诊癌症的受访者总体活动性SUD患病率与终生癌症幸存者队列相似(3.81%[SE,0.74%]),但头颈癌(18.73%[SE,10.56%])和宫颈癌幸存者(15.70%[SE,5.35%])的活动性SUD患病率更高;新确诊头颈癌幸存者中最常见的SUD为镇静剂使用障碍(9.81%[SE,9.17%])。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Some individuals are predisposed to cancer based on their substance use history, and others may use substances to manage cancer-related symptoms. Yet the intersection of substance use disorder (SUD) and cancer is understudied. Because SUD may affect and be affected by cancer care, it is important to identify cancer populations with a high prevalence of SUD, with the goal of guiding attention and resources toward groups and settings where interventions may be needed. OBJECTIVE: To describe the cancer type-specific prevalence of SUD among adult cancer survivors. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from the annually administered National Survey on Drug Use and Health (NSDUH) for 2015 through 2020 to identify adults with a history of solid tumor cancer. Substance use disorder was defined as meeting at least 1 of 4 Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) criteria for abuse or at least 3 of 6 criteria for dependence. MAIN OUTCOMES AND MEASURES: Per NSDUH guidelines, we made adjustments to analysis weights by dividing weights provided in the pooled NSDUH data sets by the number of years of combined data (eg, 6 for 2015-2020). The weighted prevalence and corresponding SEs (both expressed as percentages) of active SUD (ie, within the past 12 months) were calculated for respondents with any lifetime history of cancer and, in secondary analyses, respondents diagnosed with cancer within 12 months prior to taking the survey. Data were analyzed from July 2022 to June 2023. RESULTS: This study included data from 6101 adult cancer survivors (56.91% were aged 65 years or older and 61.63% were female). Among lifetime cancer survivors, the prevalence of active SUD was 3.83% (SE, 0.32%). Substance use disorder was most prevalent in survivors of head and neck cancer (including mouth, tongue, lip, throat, and pharyngeal cancers; 9.36% [SE, 2.47%]), esophageal and gastric cancer (9.42% [SE, 5.51%]), cervical cancer (6.24% [SE, 1.41%]), and melanoma (6.20% [SE, 1.34%]). Alcohol use disorder was the most common SUD (2.78% [SE, 0.26%]) overall and in survivors of head and neck cancer, cervical cancer, and melanoma. In survivors of esophageal and gastric cancers, cannabis use disorder was the most prevalent SUD (9.42% [SE, 5.51%]). Among respondents diagnosed with cancer in the past 12 months, the overall prevalence of active SUD was similar to that in the lifetime cancer survivor cohort (3.81% [SE, 0.74%]). However, active SUD prevalence was higher in head and neck (18.73% [SE, 10.56%]) and cervical cancer survivors (15.70% [SE, 5.35%]). The distribution of specific SUDs was different compared with that in the lifetime cancer survivor cohort. For example, in recently diagnosed head and neck cancer survivors, sedative use disorder was the most common SUD (9.81% [SE, 9.17%]). CONCLUSIONS AND RELEVANCE: Findings of this study suggest that SUD prevalence is higher among survivors of certain types of cancer; this information could be used to identify cancer survivors who may benefit from integrated cancer and SUD care. Future efforts to understand and address the needs of adult cancer survivors with comorbid SUD should prioritize cancer populations in which SUD prevalence is high.
引用
- Jones KF, Osazuwa-Peters OL, Des Marais A, et al. Substance Use Disorders Among US Adult Cancer Survivors. JAMA Oncol. 2024. PMID: 38206609. doi:10.1001/jamaoncol.2023.5785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。